Evidence or revenue: biotech's middle ground is where deals go to die

Two ends of the market, and a gap between them

Read this week's deal flow as a single market and a pattern emerges. Capital is moving toward assets that have either proved something in the clinic or already sell. Companies holding neither are being sold off in pieces or are taking their strategic options to the market. The middle ground, where a story rests on potential and nothing has yet confirmed it, is shrinking.

Proof gets a buyer; a miss gets a review

Silence Therapeutics reported a $12.4M third-quarter loss and $247.7M in cash, alongside positive Phase 2 divesiran data in polycythemia vera. It also has a pending acquisition by Merck KGaA. The material does not say how the data and the deal were sequenced, and we should not pretend it does. But the company that arrives at a sale with a clean readout and a funded balance sheet negotiates from a different place than one that does not.

Longeveron shows the other side. Laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome in ELPIS II. The company is seeking an FDA meeting and has started a strategic alternatives review that could end in a sale or merger. One trial result moved it from developer to seller.

Gedeon Richter and Eli Lilly show what buyers do with a credible asset when they do not buy the whole company. Lilly gets exclusive worldwide rights to develop estetrol combinations in women's health and cardiometabolic disease, plus a US co-commercialisation option on FYLREVY. It will also buy about $15M of Richter shares. That is a bet on specific science, structured to be proportionate.

Revenue is the other safe harbour

CorMedix agreed to buy substantially all of Heron Therapeutics' assets. That brings four marketed drugs, ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with about $150 million in trailing-12-month net revenue, backed by a Pharmakon term loan. Here the buyer is paying for sales that already exist. Alcon, reporting third-quarter sales up 5% to $2.7bn on dry eye and surgical equipment launches, announced its planned purchase of Neurotech Pharmaceuticals from a position of operating strength.

Then look at what happens in between. Theriva sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront. Whatever the long-term value, that figure shows how little an unfunded, non-core programme can fetch on the day it has to be moved.

The strongest counter-argument

The best objection is that early-stage assets still trade. Kiora has licensed Senju's oral calpain inhibitor KIO-401 for retinal artery occlusion outside Asia and has asked the FDA for a pre-IND meeting and orphan drug designation. Ocugen has licensed OCU400 to Celairis for Australia, New Zealand and ASEAN ahead of Phase 3 top-line data expected in the first quarter of 2027. Both are deals on unproven science. If the middle were closing, they should not exist.

But look at the shape of them. Kiora takes one defined asset with a clear regulatory next step. Ocugen's partner is buying regional rights before a data event that is dated and close. Neither is a bet on a platform's promise. They are narrow, milestone-anchored transactions, which supports the thesis: even early deals are being cut down to something checkable.

What this means

The practical lesson is that value is increasingly set at specific moments: a readout, an approval, a revenue line. Companies that reach those moments with options intact do well. Companies that reach them without cash, focus or a second path end up with a strategic review or a $350,000 asset sale.